Teladoc (TDOC) Tops Q2 EPS by 6c, Revenue Misses, Offers Guidance
Teladoc (NYSE: TDOC) reported Q2 EPS of ($0.28), $0.06 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $642 million versus the consensus estimate of $649.49 million.
Financial Outlook
Teladoc Health is withdrawing the financial outlook for the Full Year of 2024 for its Consolidated operations and its BetterHelp segment that was last provided on April 25, 2024. It is also withdrawing its three year outlook on its Consolidated operations and its operating segments that had last been reaffirmed on April 25, 2024.
The outlook provided for the Integrated Care segment is based on current market conditions and expectations and what we know today. Accordingly, we believe our outlook ranges provide a reasonable baseline for future financial performance.
Integrated Care
| For the third quarter of 2024, we expect | |
| Revenue growth percentage (year-over-year) | (1)% - 2% |
| Adjusted EBITDA margin | 14.5% - 16.0% |
| U.S. Integrated Care Members (2) | 92.5 - 93.5 million |
| For the full year of 2024, we expect | |
| Revenue growth percentage (year-over-year) | Low single digits to mid-single digits |
| Adjusted EBITDA margin expansion (year-over-year) | +150bps to +200bps |
| U.S. Integrated Care Members (2) | 92.5 - 94.0 million |
For earnings history and earnings-related data on Teladoc (TDOC) click here.